These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15540524)

  • 21. [Contrast-induced acute renal failure].
    Giannattasio M
    G Ital Nefrol; 2005; 22(3):217-25. PubMed ID: 16001365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
    Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
    Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome].
    Lüke C; Dohmen C; Dietlein TS; Brunner R; Lüke M; Krieglstein GK
    Klin Monbl Augenheilkd; 2007 Dec; 224(12):932-4. PubMed ID: 18260057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute encephalopathy associated with the use of intravenous immunoglobulin. Report of one case].
    Soto V A; Cartier R L
    Rev Med Chil; 2011 Oct; 139(10):1340-3. PubMed ID: 22286735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute renal failure after large doses of intravenous immune globulin.
    Haskin JA; Warner DJ; Blank DU
    Ann Pharmacother; 1999; 33(7-8):800-3. PubMed ID: 10466908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk.
    Dantal J
    Am J Nephrol; 2013; 38(4):275-84. PubMed ID: 24051350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
    Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrotoxicity of intravenous immunoglobulin.
    Levy JB; Pusey CD
    QJM; 2000 Nov; 93(11):751-5. PubMed ID: 11077032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Practical comments on the use of immunoglobulins].
    Lewandowicz-Uszyńska A; Swierkot J
    Pol Merkur Lekarski; 2011 Jun; 30(180):448-51. PubMed ID: 21751557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Jun; 48(24):518-21. PubMed ID: 10401909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Home self-administration of intravenous immunoglobulin therapy in children.
    Kobayashi RH; Kobayashi AD; Lee N; Fischer S; Ochs HD
    Pediatrics; 1990 May; 85(5):705-9. PubMed ID: 2109852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
    Alshekhlee A; Hussain Z; Sultan B; Katirji B
    J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Varenicline-associated acute renal failure.
    Bird ML; Vesta KS
    Ann Pharmacother; 2008 Dec; 42(12):1908-11. PubMed ID: 18984856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
    Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
    Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
    Sapir T; Blank M; Shoenfeld Y
    Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin, blood viscosity and myocardial infarction.
    Fisman DN; Smilovitch M
    Can J Cardiol; 1997 Aug; 13(8):775-7. PubMed ID: 9284845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.